Effective vaccine coverage is urgently needed to tackle the COVID-19 pandemic. Inactivated vaccines have been introduced in many countries for emergency usage, but only provided limited protection. Heterologous vaccination a promising strategy maximise immunogenicity. Here, we conducted phase I, randomised control trial observe safety and immunogenicity after an intradermal boost, using fractional dosage (1:5) of BNT162b2 mRNA healthy participants Songkhla, Thailand. In total, 91 volunteers...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. Two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) have been shown to be insufficient protect against variants concern (VOCs), while viral vector vaccines remain protective the infection. Herein, we conducted preliminary study evaluate safety and immunity in adult population who received conventional dosage-regimen vaccine; with additional intradermal ChAdOx1 nCoV-19 reciprocal dosage (1:5). An...

The anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody is associated with rapidly progressive interstitial lung disease (RP-ILD) and clinically amyopathic dermatomyositis (CADM). predictors of treatment response would help in classifying the subgroups decision-making. Here, we aimed to report an observational skin lesion that might be a grave prognosis six patients anti-MDA5 antibody-positive ILD.This case series included 6 ILD patients, who were admitted Songklanagarind...

A practical booster vaccine is urgently needed to control the coronavirus disease (COVID-19) pandemic. We have previously reported safety and immunogenicity of a fractional intradermal booster, using BNT162b2 mRNA in healthy volunteers who had completed two doses inactivated SARS-CoV-2 vaccine. In this study, an intramuscular at full dosage was used as control, half-dose vaccination included for reciprocal comparison. Detailed T-cell studies are essential understand cellular responses...

Tuberculosis (TB) is an infectious disease with the burden concentrated in low- and middle-income countries. Systemic lupus erythematosus (SLE) autoimmune associated widespread inflammation that prevalent some TB endemic areas including East Africa parts of Southeast Asia. SLE patients are known to be at higher risk becoming infected M. tb, developing disease. However, immune mechanisms underlying this susceptibility not well understood, particularly absence immunosuppressive drugs. We...

Reports on vaccine immunogenicity in patients with systemic autoimmune rheumatic diseases (SARDs) have been inconclusive. Here, we report the of heterologous prime-boost an inactivated followed by adenoviral vector SARDs using anti-RBD antibodies, neutralizing capacity against Omicron BA.2 [plaque-reduction neutralization test (PRNT)], T cell phenotypes, and effector cytokine production at 4 weeks after vaccination. SARD had lower median (IQR) anti-RBD-IgG levels function variant than...

The administration of viral vector and mRNA vaccine booster effectively induces humoral cellular immune responses. Effector T cell responses after fractional intradermal (ID) vaccination are comparable to those intramuscular (IM) boosters. Here, we quantified vaccination. ChAdOx1 nCoV-19 induced higher numbers S1-specific CD8

<h3>Objective</h3> To investigate the clinical and biomarkers factors predicting a requirement for intensive therapy or time to from diagnosis of Systemic Lupus Erythematosus (SLE). <h3>Methods</h3> We conducted retrospective longitudinal study all patients with SLE two Leeds Cohort databases (CONVAS DEFINITION) over 30 years follow-up. Data collection included demographics, characteristics, 2019 EULAR/ACR classification criteria score, SLEDAI-2K routine immunological tests. The primary...

Nowadays, dapsone is more commonly used in some dermatologic and inflammatory conditions other than leprosy. Even though it has excellent therapeutic efficacy, its side effects are of common concern. Although immune mediated drug hypersensitivity less common, can be fatal. Sulfone syndrome a unique presentation that occurs (DHR). Here, we report on 22-year-old female who was prescribed one month for dermatitis. She developed generalized maculopapular rash low-grade fever observed her sclera...

<h3>Background:</h3> B cell depletion is widely used to treat SLE. Rituximab (RTX) already used, and other agents such as obinutuzumab, CD19 CAR-T are being developed. However, cells have diverse roles in SLE, including immunostimulatory immunoregulatory roles. The mechanism of action these therapies not fully understood, nor do we know how identify patients suitable for therapies. Clinical imaging data from a recent trial SLE arthritis (ROOTS) suggested two-phase response pattern with...

<h3>Background:</h3> ANA-RMDs arise from a common At-Risk population defined by ANA antibodies with or without clinical symptoms. Accumulating evidence indicates that positivity is complex and dynamic immune dysregulation in which the majority of individuals remain clinically well. Most previous analyses this have focussed on gene expression antibody status, but it unclear how these are regulated at functional protein level. <h3>Objectives:</h3> To investigate using identify biomarkers for...

<h3>Background:</h3> The consideration of intensive therapy in SLE depends on disease severity, resistance, or reimbursement issues. Evaluating the baseline predicting factors for earlier decisions to initiate high-risk patients is an unmet need. Thus, we assessed predictors requirements such a novel early strategy prevent severe and accrual damage. <h3>Objectives:</h3> To investigate clinical biomarkers time-to-requirement from diagnosis. <h3>Methods:</h3> We conducted retrospective...

<h3>Background:</h3> Achievement of disease remission or lupus low activity state (LLDAS) is a targeted strategy convinced by the current SLE management recommendations. However, knowledge gap exists in how immunological profiles and clinical outcomes diverge between LLDAS subgroups. <h3>Objectives:</h3> This study aims to evaluate using cytokine measurement two <h3>Methods:</h3> prospective cohort was conducted at Songklanagarind Hospital, Thailand, from January December 2023. We included...

<h3>Background:</h3> 2019 EULAR/ACR Systemic Lupus Erythematosus (SLE) criteria were validated for classification from cases of established SLE compared to other diseases (sensitivity 0.96 (0.95-0.98); specificity 0.93 (0.91-0.95))¹, but have not been assessed as diagnostic in an undiagnosed cohort ANA positive patients clinically suspected SLE. <h3>Objectives:</h3> In with and symptoms represent SLE, evaluate performance against a) consultants' diagnosis after 3 years follow-up...

Lupus nephritis (LN) is a common and severe organ manifestation in patients with systemic lupus erythematosus (SLE). LN can present alone or accompanying extra-renal symptoms. The prevalence severity vary depending on ethnicity, genetics, environmental exposure. However, the presence of SLE surrogate indicator disease severity, frequent relapse, increased chronic kidney (CKD), mortality risks. current conventional standard treatments for include corticosteroids, immunosuppressive drugs,...

Patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) have an increased risk of premature death. Different subtypes, predictors, and ethnicities may affect the overall survival. However, survival Thai AAV patients has not been reported. We examined mortality prognosis these patients.This medical record review study included adult patients, admitted to Songklanagarind Hospital from 2007 2017. Antineutrophil was diagnosed according 1990 American College Rheumatology...

Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce. In this study, we reported humoral immunogenicity of an 90–180 days heterologous CoronaVac/ChAdOx1 nCoV-19 (n = 19) or homologous ChAdOx1 14) vaccination by measuring anti-SARS-CoV-2 receptor binding domain (RBD) IgG levels at one and three months vaccination. This study included 33 ARDs [78.8% women;...

Adult onset immunodeficiency associated with anti-interferon-gamma autoantibodiesis an emerging medical issue worldwide especially in South-east Asia. Most patientspresent disseminated non-tuberculous mycobacteria (NTM) infection and otheropportunistic infections. In addition to standard antimicrobial therapy, immunomodulatoror immunosuppressive drug seem play a role some cases.In the present study, we thoroughly reviewed pathogenesis, clinical features,laboratory diagnosis, modalities of...

Background: Alongside vaccine hesitancy, impaired and waning immunity in autoimmune rheumatic diseases (ARDs) are barriers to immunization.The timeframe of ARD remains unclear. Objectives:We aimed examine the humoral immunogenicity a cohort patients who received heterologous inactivated followed by adenoviral vector SAR-CoV-2 at 3-month follow-up. Methods:The levels SARS-CoV-2 anti-RBD IgG were evaluated 1 3 months adults with ARDs (n = 29) age-and sex-matched healthy controls (HC) that...

<h3>Background</h3> Add-on intravenous pulse methylprednisolone (IVMP) is a strategy to reduce cumulative glucocorticoids (GCs) doses for treating proliferative lupus nephritis (LN). However, the benefit still under debate. This study compares efficacy and safety of add-on IVMP versus GCs alone in Thai patients with LN receiving monthly cyclophosphamide (IVCY). <h3>Methods</h3> enrolled 63 biopsy-proven who underwent induction therapy Songklanagarind hospital, from January 2009 December...

<h3>Background and aims</h3> Bacteremia significantly affects mortality rate in SLE. It characterises differently across diverse geographic area. This study aimed to identify risk factors for bacteremia Thai SLE patients. <h3>Methods</h3> A retrospective case-control recruited patients who admitted between 2004 2014. Cases with significant from microbiology database were matched diagnosis. Controls selected the year of case's hospital admission a ratio 1:4. The admissions elective procedure...

Background: Neutralisation of the SARS-CoV-2-Omicron BA·2 variant in patients with systemic autoimmune rheumatic diseases (SARDs) has not been reported, and information on cellular response is inconclusive. Heterologous prime-boost vaccination a promising strategy for improving immunogenicity. We report vaccine immunogenicity an inactivated followed by adenoviral vector SARDs.Methods: This prospective study investigated CoronaVac ChAdOx1 nCoV-19 SARDs vs· age- sex-matched healthy controls....